THAT

Thalia Therapeutics PLC

Health Care First-pass screen £4.79m

300/1000 Overall fit

AI beneficiary 35% 30

Operating leverage 25% 25

Valuation 25% 30

Downside protection 15% 35

First-pass take

Pre-clinical biotech with zero AI exposure. Nuvec® gene delivery platform shows early promise (positive in vivo IBD data) but company remains loss-making (£1.2m operating loss, £7.3k revenue) with discretionary cost structure. Recent £1.75m fundraise (Apr 2025) extends cash runway to 12+ months but no clear commercialization path.

Flags

pre-clinicalloss-makingcash-burncapital-intensive-rdmicro-capfundraising-dependentno-valuation-datano-ai-exposure